European Society for Medical Oncology Preceptorship on Lung Cancer 2023 Lisbon

Description

+ Include: 27 videos + 28 pdfs, size: 2.98 GB

+ Target Audience: oncologist

+ Sample video: contact me for sample video

+ Information:

+ Topics:

ESMO-Preceptorship-on-Lung-Cancer-2023-Lisbon-Programme.pdf
Session 1 Lung Cancer Screening.mp4
Session 1 Lung Cancer Screening.pdf
Session 1 Primer of Pathology in Thoracic Malignancies.mp4
Session 1 Primer of Pathology in Thoracic Malignancies.pdf
Session 1 Principles of Molecular Testing in Lung Cancer (Tissue, Liquid).mp4
Session 1 Principles of Molecular Testing in Lung Cancer (Tissue, Liquid).pdf
Session 1 Smoking Cessation.mp4
Session 1 Smoking Cessation.pdf
Session 2 Ongoing Clinical Trials in Operable NSCLC.mp4
Session 2 Ongoing Clinical Trials in Operable NSCLC.pdf
Session 2 Principles of Radiotherapy.mp4
Session 2 Principles of Radiotherapy.pdf
Session 2 Principles of Surgical Management.mp4
Session 2 Principles of Surgical Management.pdf
Session 2 Principles of Systemic Treatment (Adjuvant, Neoadjuvant).mp4
Session 2 Principles of Systemic Treatment (Adjuvant, Neoadjuvant).pdf
Session 3 Approach to Patients with Brain Metastases.mp4
Session 3 Approach to Patients with Brain Metastases.pdf
Session 3 Immunotherapy Chemo-Immunotherapy.mp4
Session 3 Immunotherapy Chemo-Immunotherapy.pdf
Session 3 Immunotherapy Complications.mp4
Session 3 Immunotherapy Complications.pdf
Session 3 Oligometastatic NSCLC.mp4
Session 3 Oligometastatic NSCLC.pdf
Session 4 How Do I Treat Patients with EGFR Mutations.mp4
Session 4 How Do I Treat Patients with EGFR Mutations.pdf
Session 4 How Do I Treat Patients with Gene Fusions.mp4
Session 4 How Do I Treat Patients with Gene Fusions.pdf
Session 4 How Do I Treat Patients with HER2 Mutations, BRAF Mutations, MET Mutations.mp4
Session 4 How Do I Treat Patients with HER2 Mutations, BRAF Mutations, MET Mutations.pdf
Session 4 Novel Targets (KRAS and Others).mp4
Session 4 Novel Targets (KRAS and Others).pdf
Session 5 Clinical Case Presentations from the Audience – A Case of Tuberculosis in a Patient Receiving Immune Checkpoint Inhibitor.mp4
Session 5 Clinical Case Presentations from the Audience – A Case of Tuberculosis in a Patient Receiving Immune Checkpoint Inhibitor.pdf
Session 5 Clinical Case Presentations from the Audience – HER2-mutated Non-Small Cell Lung Cancer.mp4
Session 5 Clinical Case Presentations from the Audience – HER2-mutated Non-Small Cell Lung Cancer.pdf
Session 5 Clinical Case Presentations from the Audience – Neurological Toxicity Lorlatinib.mp4
Session 5 Clinical Case Presentations from the Audience – Neurological Toxicity Lorlatinib.pdf
Session 5 Clinical Case Presentations from the Audience – NSCLC- The Value of Genomic Re-evaluation on Progression.mp4
Session 5 Clinical Case Presentations from the Audience – NSCLC- The Value of Genomic Re-evaluation on Progression.pdf
Session 5 Clinical Case Presentations from the Audience – Time-Lapse of an EGFR Mutation.mp4
Session 5 Clinical Case Presentations from the Audience – Time-Lapse of an EGFR Mutation.pdf
Session 5 Clinical Case Presentations from the Audience – To Treat, or not to Treat, That is the Question.mp4
Session 5 Clinical Case Presentations from the Audience – To Treat, or not to Treat, That is the Question.pdf
Session 6 Current Management of Mesothelioma.mp4
Session 6 Current Management of Mesothelioma.pdf
Session 6 Current Management of SCLC.mp4
Session 6 Current Management of SCLC.pdf
Session 6 Current Management of Thymoma Thymic Carcinoma.mp4
Session 6 Current Management of Thymoma Thymic Carcinoma.pdf
Session 6 Principles of Follow-up after Treatment of Thoracic Malignancies.mp4
Session 6 Principles of Follow-up after Treatment of Thoracic Malignancies.pdf
Welcome and Introduction.mp4
Welcome and Introduction.pdf